dc.contributor.author |
Weecharangsan W. |
|
dc.contributor.author |
Yu B. |
|
dc.contributor.author |
Zheng Y. |
|
dc.contributor.author |
Liu S. |
|
dc.contributor.author |
Pang J.X. |
|
dc.contributor.author |
Lee L.J. |
|
dc.contributor.author |
Marcucci G. |
|
dc.contributor.author |
Lee R.J. |
|
dc.date.accessioned |
2021-04-05T03:37:16Z |
|
dc.date.available |
2021-04-05T03:37:16Z |
|
dc.date.issued |
2009 |
|
dc.identifier.issn |
15438384 |
|
dc.identifier.other |
2-s2.0-72049109189 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/14785 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-72049109189&doi=10.1021%2fmp900150g&partnerID=40&md5=61f2c9acba8df78794d86ee7603ae159 |
|
dc.description.abstract |
Human serum albumin (HSA)-coated liposomal formulations were synthesized and evaluated for the delivery of antisense oligodeoxyribonucleotide (ODN) G3139 in KB human oral carcinoma cells. Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/α-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with G3139 and coated with HSA were investigated for Bcl-2 downregulating activity. Cellular uptake of HSA-coated liposome-ODN complexes was more efficient than the uncoated liposome-ODN complexes. Treatment of the cells with HSA-coated liposome-ODN complexes resulted in efficient Bcl-2 mRNA downregulation that was approximately 3-fold greater than with uncoated liposomes (p < 0.05) and 6-fold greater than with free ODN. The transfection efficiency of liposome-ODN complexes coated with HSA was dependent on the concentration of HSA used and on the contents of α-helix and β-strand in HSA. HSA-coated liposomes are effective delivery vehicles for antisense ODN. © 2009 American Chemical Society. |
|
dc.subject |
alpha tocopherol |
|
dc.subject |
dimethyldioctadecyl ammonium bromide |
|
dc.subject |
human serum albumin |
|
dc.subject |
liposome |
|
dc.subject |
oblimersen |
|
dc.subject |
phosphatidylcholine |
|
dc.subject |
protein bcl 2 |
|
dc.subject |
unclassified drug |
|
dc.subject |
alpha helix |
|
dc.subject |
article |
|
dc.subject |
carcinoma cell |
|
dc.subject |
complex formation |
|
dc.subject |
controlled study |
|
dc.subject |
down regulation |
|
dc.subject |
drug formulation |
|
dc.subject |
genetic transfection |
|
dc.subject |
human |
|
dc.subject |
human cell |
|
dc.subject |
mouth carcinoma |
|
dc.subject |
priority journal |
|
dc.subject |
Blotting, Western |
|
dc.subject |
Cell Line, Tumor |
|
dc.subject |
Circular Dichroism |
|
dc.subject |
Electrophoresis, Agar Gel |
|
dc.subject |
Humans |
|
dc.subject |
Liposomes |
|
dc.subject |
Proto-Oncogene Proteins c-bcl-2 |
|
dc.subject |
Reverse Transcriptase Polymerase Chain Reaction |
|
dc.subject |
Serum Albumin |
|
dc.subject |
Thionucleotides |
|
dc.title |
Efficient delivery of antisense oligodeoxyribonucleotide G3139 by human serum albumin-coated liposomes |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Molecular Pharmaceutics. Vol 6, No.6 (2009), p.1848-1855 |
|
dc.identifier.doi |
10.1021/mp900150g |
|